Latest / ESWI Airborne's Podcast / Finding Your Place in Science
Transcript
- 0:00ESWI Secretariat: Welcome to ESWI Airborne.
- 0:02ESWI Secretariat: In this series featuring our early career scientists community, we explore how the next generation is shaping the future of respiratory virus research.
- 0:10ESWI Secretariat: This series is made possible thanks to the kind support of CSL Seqirus and Sanofi Pasteur.
- 0:40Jane Barratt (Host): Welcome to ESWI Airborne, the podcast of the European Scientific Working Group on Influenza. I'm Jane Barrett and have the great pleasure of hosting today's conversation.
- 0:45Jane Barratt (Host): ESWI is a community built on evidence, curiosity, and collaboration.
- 0:51Jane Barratt (Host): Today, in our Early Career Scientists series, we highlight two people who will certainly help to shape the next decades of influenza and respiratory virus research.
- 1:04Jane Barratt (Host): The winners of Claude Hannoun Prize for Best Body of Work, Dr.
- 1:09Jane Barratt (Host): Kevin Ciminski, and the Young Scientist Vaccine Innovation Award recipient, Dr.
- 1:15Jane Barratt (Host): Marios Koutsakos.
- 1:18Jane Barratt (Host): We are really wanting their views about what it means to build a scientific life, finding your niche, shaping a lab, developing critical skills, and contributing to a global scientific community.
- 1:32Jane Barratt (Host): So let's start with some introductions of our experts.
- 1:36Jane Barratt (Host): Kevin Ciminski is an independent research group leader at the Institute of Virology at the University Medical Center Freiburg in Germany.
- 1:46Jane Barratt (Host): His work focuses on virus host interactions of emerging zoonotic influenza viruses with particular interest in how these viruses adapt, trigger immune responses, and drive immunopathology.
- 2:02Jane Barratt (Host): Welcome, Kevin.
- 2:03Jane Barratt (Host): It's good to have you with us today.
- 2:05Jane Barratt (Host): And also, we have the great pleasure of talking with Marios, who is a group leader of the Doherty Institute in Melbourne, Australia, where he leads research on influenza B viruses, immune imprinting, and the development of broader and more durable influenza vaccine strategy.
- 2:25Jane Barratt (Host): His primary work in the molecular virology and antigenic evolution of influenza B, followed by postdoctoral research into immunity following influenza on SARS-CoV-2 vaccination or influenza.
- 2:42Jane Barratt (Host): So welcome to both of you.
- 2:44Jane Barratt (Host): It's good to have you here.
- 2:45Jane Barratt (Host): And Kevin, you're coming from Germany, and Marios, you're in my home country of Australia, I understand.
- 2:52Jane Barratt (Host): Is that right?
- 2:53Marios Koutsakos: Correct, yes.
- 2:55Jane Barratt (Host): Good.
- 2:55Jane Barratt (Host): And Kevin, Germany?
- 2:57Kevin Ciminski: Germany is right, yes.
- 2:58Kevin Ciminski: Thanks for the introduction, Jane.
- 3:01Jane Barratt (Host): Good pleasure.
- 3:02Jane Barratt (Host): Look, let's first of all just to unravel the core mechanisms.
- 3:06Jane Barratt (Host): And this question goes to both of you.
- 3:09Jane Barratt (Host): What single fundamental question about your viruses or immune imprinting are you currently most focused on?
- 3:18Jane Barratt (Host): So, Kevin, let's start off with you.
- 3:21Kevin Ciminski: Yeah, as you just mentioned, I just got recently funded for deciphering the interplay of influenza viruses and the immune system.
- 3:31Kevin Ciminski: So, what is my main interest right now is how influenza viruses infect macrophages, as one of the immune cells that are at the center of infection, and how infection of these macrophages shapes the immune response.
- 3:52Kevin Ciminski: So we want to understand how the infection can lead to immunopathology and what we can learn in order to interfere with severe causes of illness triggered by exacerbated disease, by macrophages releasing cytokines.
- 4:13Jane Barratt (Host): Well, congratulations on the grant.
- 4:15Jane Barratt (Host): That's probably well deserved.
- 4:17Jane Barratt (Host): So, Marios, let's turn to you on immune imprinting.
- 4:20Jane Barratt (Host): Tell us a little bit about what are the single fundamental questions that you're really researching.
- 4:26Marios Koutsakos: Yes, our recent findings suggest that some people have somehow over their lifetime developed antibodies that are broadly protective against many different variants of influenza B viruses.
- 4:38Marios Koutsakos: And so we're trying to understand how that kind of immunity develops and what part of the viruses these antibodies target, and then how can we instruct the immune system to do the same using vaccines so we can establish broadly protective immunity against influenza B viruses?
- 4:57Jane Barratt (Host): Question without notice.
- 4:59Jane Barratt (Host): I'm really interested.
- 5:00Jane Barratt (Host): You know, you are at the forefront of science, both of you.
- 5:04Jane Barratt (Host): But how is that going to impact populations in the end?
- 5:09Jane Barratt (Host): Would you like to make a comment of that?
- 5:11Jane Barratt (Host): Either Kevin or Marios?
- 5:14Marios Koutsakos: Sure, yeah.
- 5:15Marios Koutsakos: Kevin, go ahead.
- 5:17Kevin Ciminski: I mean, we have these zoonotic infections right now everywhere around the globe with avian influenza viruses, for example, because they are globally spreading, they are now in dairy cattle, and this leads to ever increasing numbers of humans being infected with avian influenza.
- 5:35Kevin Ciminski: And these avian influenza viruses are well known to, for example, infect macrophages, leading to the severe cases of disease.
- 5:43Kevin Ciminski: And we still don't know why, but it is somehow related to macrophages.
- 5:47Kevin Ciminski: So if we understand what is responsible for the severe causes of disease, like what are the triggers, inflammatory responses, they would definitely open up some new therapeutic options, for example.
- 6:02Kevin Ciminski: Something that can be used to cure these individuals.
- 6:07Jane Barratt (Host): Okay, thanks.
- 6:08Jane Barratt (Host): Marios, your perspectives?
- 6:10Marios Koutsakos: Yeah, I mean, our main goal is to try and reduce the impact, the clinical impact of influenza B viruses.
- 6:16Marios Koutsakos: So influenza B viruses have been generally overlooked compared to influenza A viruses, but they account on average for a quarter of influenza infections every year.
- 6:26Marios Koutsakos: The majority of those infections are in school-age children and adolescents, and in those age groups, influenza B viruses can develop severe complications and even cause fatal disease.
- 6:38Marios Koutsakos: And so our overarching aim is to try and reduce that burden for those populations.
- 6:44Jane Barratt (Host): You know, that's really interesting.
- 6:46Jane Barratt (Host): I kind of sit in the latter half of life, so you know, in my work, so it's really interesting to hear that.
- 6:52Jane Barratt (Host): So let's move on to you know, your scientific place.
- 6:56Jane Barratt (Host): It's always fascinating to understand, Kevin, you know, why you chose this field.
- 7:01Jane Barratt (Host): So your work on zoonotic and bat-derived influenza viruses really sits at a rare frontier.
- 7:08Jane Barratt (Host): How did you choose this direction?
- 7:11Kevin Ciminski: Oh, that was actually by accident.
- 7:13Kevin Ciminski: So I was given a completely different PhD topic at the beginning of my scientific career, and I told my supervisor that I don't like this topic.
- 7:25Kevin Ciminski: It is not my topic.
- 7:27Kevin Ciminski: There was basically not a match.
- 7:29Kevin Ciminski: And then we sit together and we're discussing options, and then we came up with this bat influenza viruses.
- 7:36Kevin Ciminski: It was also one thing that people were working in our lab, and we identified that we basically don't know what the zoonotic potential of these bat flu viruses is.
- 7:46Kevin Ciminski: So we thought rather than focusing on this, at least to me, not so interesting topic, we should switch gears a little bit and go into the direction of the zoonotic aspect of these bat flu viruses.
- 8:02Jane Barratt (Host): So opportunistic, which is really not so rare, but it's an opportunistic focus.
- 8:12Jane Barratt (Host): Now, what about you, Marios?
- 8:13Jane Barratt (Host): How did you select this field or did you?
- 8:17Marios Koutsakos: Well, opportunistically as well, I would say.
- 8:19Marios Koutsakos: Serendipity for the most part.
- 8:22Marios Koutsakos: As an undergraduate student, quite a while ago now, I worked with Wendy Barkley for a summer research placement.
- 8:29Marios Koutsakos: And I think by chance I was given a project on influenza B viruses.
- 8:33Marios Koutsakos: And I thought that was quite interesting and captivating.
- 8:37Marios Koutsakos: But sort of starting to look into the project on influenza B viruses, I came to realize how overlooked influenza B viruses are and all the different questions that are that we have for influenza B, but we don't have answers to.
- 8:50Marios Koutsakos: And I think that sort of stayed with me for all that time since then.
- 8:56Jane Barratt (Host): It's very interesting, isn't it?
- 8:58Jane Barratt (Host): So often it's opportunistic and not what you've planned.
- 9:02Jane Barratt (Host): I want us to sort of step, zoom out now and talk about how science demands such deep expertise, but you really need a wide lens to be able to then focus on your particular subject area.
- 9:19Jane Barratt (Host): How do you balance that focused approach with the broader question when you're dealing with respiratory virus science?
- 9:29Jane Barratt (Host): So, Kevin, do you have any perspectives about that?
- 9:33Kevin Ciminski: Yeah, that's actually a good question.
- 9:35Kevin Ciminski: And so to me, a question is always interesting when you can explain it in simple words to your parents.
- 9:43Kevin Ciminski: So if they get the research question, I think it's an interesting research question.
- 9:47Kevin Ciminski: If you have to talk a lot, describe a lot, that's super complicated and people won't get it.
- 9:53Kevin Ciminski: And you probably are not able to create a bigger picture.
- 9:57Kevin Ciminski: So if I can create a big picture and describe a research project in simple words, I think that's a good research project.
- 10:04Kevin Ciminski: That's what we usually try.
- 10:07Jane Barratt (Host): Yeah, and Marios, you were nodding as Kevin was talking.
- 10:11Jane Barratt (Host): Is that how you kind of deal with these zooming out and coming back in?
- 10:17Marios Koutsakos: Yeah, and also I think sometimes there might be questions that we are looking into for influenza B specifically, but influenza B doesn't exist in a vacuum, and we have to stay up to date with the influenza A field, and advances in that field can be applicable to influenza B.
- 10:33Marios Koutsakos: And also think the reverse, there might be more generalizable principles that come out of influenza B research that can inform influenza A.
- 10:41Marios Koutsakos: And in a broader respiratory virus I guess aspect a lot of the techniques we use to understand immunity to influenza viruses is directly applicable to other respiratory viruses.
- 10:54Marios Koutsakos: And that was something a lot of people utilized during the SARS-CoV-2 pandemic, where a lot of people pivoted from their influenza or other respiratory virus research to contribute to the SARS-CoV-2 pandemic.
- 11:08Jane Barratt (Host): You really have to be very adaptable, not only in your techniques, but responding to the environmental variants as well.
- 11:16Jane Barratt (Host): So thank you.
- 11:17Jane Barratt (Host): I want to go on to the transformative nature of your work.
- 11:23Jane Barratt (Host): In the next five years, and five years goes very quickly, what's the single most transformative discovery you hope to publish?
- 11:34Jane Barratt (Host): Well, we'll go to Marios first, what do you expect to be publishing on in five years?
- 11:41Marios Koutsakos: I mean, we hope to make advances in the design of broadly acting vaccines, as I mentioned, but one of the more exciting questions we're trying to address is whether influenza B viruses are really restricted to humans and to what extent they exist in animals.
- 11:58Marios Koutsakos: And I would like to think that in the next five years we have more conclusive answers to some of the questions we have at the moment.
- 12:06Marios Koutsakos: They're at more preliminary stages, but we have some exciting findings on that.
- 12:12Jane Barratt (Host): So we can expect some articles within the next five years from you and your team.
- 12:19Marios Koutsakos: I would hope so.
- 12:22Jane Barratt (Host): I need more confidence, Marios.
- 12:24Marios Koutsakos: I can't go on the record saying that I will publish that in five years, because what if I don't?
- 12:31Jane Barratt (Host): So, Kevin, you know what's the big transformative discovery of you and your team in the next five years?
- 12:39Kevin Ciminski: I think it will be about the role of macrophages.
- 12:43Kevin Ciminski: So we know these cells are around, they are important to clear infection, but they can also be responsible for driving disease.
- 12:49Kevin Ciminski: And I think we will definitely shed light on the role of macrophages and how the response of these cells is influenced by influenza viruses.
- 12:59Kevin Ciminski: So we have some good ideas, and we have the leading hypothesis here that depending on the virus, the macrophage response is different.
- 13:12Kevin Ciminski: So we hope to see that depending on the virus that is infecting these macrophages, we see different host responses.
- 13:22Jane Barratt (Host): So, Kevin, question without notice what about 10 years?
- 13:26Jane Barratt (Host): Or where do you and your team expect to be in 10 years?
- 13:31Kevin Ciminski: In 10 years, we hope to apply all these insights we gained from studying bat viruses, bat influenza viruses, and influencing influenza viruses.
- 13:46Kevin Ciminski: We hope to apply all these insights, this information we gained to other emerging viruses, and there will certainly be more emerging viruses in the next 10 years because of all climate change, you name it, that will definitely lead to more zoonotic infections with different viruses, not necessarily restricted to influenza viruses.
- 14:08Kevin Ciminski: And we hope to like build a foundation of information that can be used to tackle these zoonotic viruses.
- 14:19Jane Barratt (Host): You know, you don't work in isolation.
- 14:22Jane Barratt (Host): So now I want to talk a little bit about you know building a lab and a team and a scientific home.
- 14:29Jane Barratt (Host): You know, Marios, you've grown your team at the Doherty Institute.
- 14:33Jane Barratt (Host): One of the interesting things that I want to hear from you is how do you build this culture that's collaborative rather than competitive, or is it a bit of both?
- 14:45Marios Koutsakos: I would say it's generally more collaborative.
- 14:47Marios Koutsakos: The Doherty, I think, is designed to and to promote collaboration across different members.
- 14:55Marios Koutsakos: I guess what I find from my own collaborations is that they're generally based on mutual interests, and there's a lot of that in the Doherty when it comes to influenza.
- 15:04Marios Koutsakos: And so they start based on that and then they're built on and maintained by clear communication about what everyone's aims is, what everyone's expectations are, what goals we want to achieve together, and then how we go on to do that, and then also by respecting each other's expertise and points of views, but also I guess each other's times, everyone has a lot of things to do.
- 15:27Jane Barratt (Host): But it's a very driven profession, isn't it?
- 15:30Jane Barratt (Host): You know, it's competitive in terms of you know getting your grants in and things like that.
- 15:35Jane Barratt (Host): But it seems as though you work as a team to get that over the line.
- 15:39Marios Koutsakos: I find we can achieve more together than individually.
- 15:43Marios Koutsakos: The sum of the parts is greater than what's the saying?
- 15:48Marios Koutsakos: There's a saying.
- 15:49Jane Barratt (Host): Yep, the sum of the parts is greater than the whole.
- 15:51Jane Barratt (Host): Yes, you're absolutely true.
- 15:53Jane Barratt (Host): And Kevin, you were nodding, and this is, you've only just recently, you know, probably over the last couple of years, established your own research group.
- 16:02Jane Barratt (Host): I want to know what you were completely unprepared for in developing this group.
- 16:08Jane Barratt (Host): Was there anything that really surprised you in trying to bring people together?
- 16:13Kevin Ciminski: So people are always complaining about bureaucracy, and I'm facing it right now.
- 16:20Kevin Ciminski: I was unprepared, I had no idea.
- 16:26Kevin Ciminski: So this is really time consuming to get legal permissions and stuff, get in touch with all the responsible people just for hiring candidates.
- 16:39Kevin Ciminski: So this takes like forever.
- 16:41Kevin Ciminski: It's very time consuming and has not necessarily something to do with doing science.
- 16:46Jane Barratt (Host): And isn't that such the case?
- 16:48Jane Barratt (Host): We're expecting scientists to actually be also admin people.
- 16:54Jane Barratt (Host): It would be really helpful to be able to really focus all of your energies, on your passion, but that's not the case in this world today.
- 17:04Jane Barratt (Host): Mentorships are really important in the development of young scientists.
- 17:12Jane Barratt (Host): Has there been a single mentor that you can just bring to mind and what characteristics really inspired you to be who you are today?
- 17:22Jane Barratt (Host): Marios?
- 17:24Marios Koutsakos: Yeah, I've been very fortunate to have great mentors throughout my career, both from my supervisors but also from peers.
- 17:31Marios Koutsakos: So I guess everyone provides a little bit of a different type of mentoring.
- 17:36Marios Koutsakos: My latest supervisor and mentor Stephen Ken has been very supportive of growing my independence and establishing my own team.
- 17:45Marios Koutsakos: And so I think that's been a very important, I guess, aspect of my development as an independent group leader.
- 17:55Marios Koutsakos: Not only by providing guidance and advice, but also by actively giving me opportunities to achieve and progress my goal.
- 18:02Marios Koutsakos: And that's something I try to bring in with my own team when I mentor and supervise them by trying to give them opportunities to achieve their goals.
- 18:12Jane Barratt (Host): It does take some courage to step back and create space for others.
- 18:18Jane Barratt (Host): Absolutely.
- 18:19Jane Barratt (Host): And so I think what you've talked about there is really a mentor that recognises the future of science, which is sometimes not so evident in our community.
- 18:34Jane Barratt (Host): And Kevin, what about you?
- 18:35Jane Barratt (Host): Is there a mentor that comes to mind and how did they support you in the development of your career?
- 18:43Kevin Ciminski: So if I would pick one single name, it would be my mentor during my PhD and early postdoc.
- 18:52Kevin Ciminski: He was really supportive, he was giving me all the freedom that is required to do science, and he was always challenging the hypotheses we came up in the lab, and he still does.
- 19:08Kevin Ciminski: We have a very good peer community here because of so many good scientists.
- 19:16Kevin Ciminski: So my mentor, but also the peer community here is really good in shaping the research questions, and that's something that really was helpful for becoming a good and independent researcher.
- 19:37Jane Barratt (Host): It struck me when you were talking that sometimes we need to sit with discomfort, you know, in continuing to ask the question of the question and unpack it.
- 19:49Jane Barratt (Host): And not all scientists are prepared to do that.
- 19:52Jane Barratt (Host): So to have a mentor that questions, and places you in an uncomfortable place, and search further is an ideal that you obviously take forward.
- 20:05Jane Barratt (Host): We're now going to talk to the topics of community, collaboration, and the future.
- 20:12Jane Barratt (Host): So when we talk about the community, what does the scientific community mean to you, especially in a global field?
- 20:23Jane Barratt (Host): Because we all met at the recent ESWI Conference.
- 20:27Jane Barratt (Host): So what does it do for you, this scientific community, and how helpful or not is it?
- 20:34Jane Barratt (Host): Marios?
- 20:36Marios Koutsakos: Yeah, I think for me, the scientific community is a group of people with aligned interest in advancing the influenza field and a shared vision in having an impact that helps people against this virus.
- 20:50Marios Koutsakos: And I guess what I'm finding is that sort of aligned interest and shared vision brings people together.
- 20:58Marios Koutsakos: And I've been very fortunate to establish a variety of collaborations through those international meetings, I guess we saw.
- 21:06Jane Barratt (Host): You said that you've been very fortunate, and I want to turn the tables too, because we have been very fortunate to hear your work and the work of Kevin and other early career scientists, and that's how we generate inspiration from one another.
- 21:27Jane Barratt (Host): This shared vision is so critically important in the field of science.
- 21:32Jane Barratt (Host): So, Kevin, what does the scientific community mean for you?
- 21:37Kevin Ciminski: I mean, we are all sitting in the same boat, we're having similar interests, often similar interests.
- 21:43Kevin Ciminski: And I think what we learned during the pandemic is if we collaborate and combine forces, we can be very quick and very successful.
- 21:53Kevin Ciminski: And therefore, the scientific community is completely open, and I'm really happy to collaborate.
- 22:00Kevin Ciminski: And if you are open and you are keen to collaborate, at least my take has always been people want to get in touch with you, and there are often if you come back from meetings like this, as you have a ton of collaborations or research interests that could kick off a new project.
- 22:23Kevin Ciminski: So meeting these people, these scientists is always an inspiration, a source of inspiration.
- 22:31Jane Barratt (Host): I certainly agree, these conferences are so very important, and the ESWI gives the opportunity to exchange knowledge, but also, sit and understand where there's intersections of work.
- 22:47Jane Barratt (Host): Where can early career scientists have the biggest impact in influenza and respiratory virus research over the next decade?
- 22:56Jane Barratt (Host): Kevin, where do you think that we're going with this?
- 23:01Kevin Ciminski: This goes probably into Marios's direction.
- 23:03Kevin Ciminski: So if some early career scientists can design some vaccine against emerging pandemic strains, we are all safe.
- 23:14Kevin Ciminski: So I think vaccine approaches or some immune approaches to prevent emerging viruses is definitely a very hot topic.
- 23:23Kevin Ciminski: If you can control this one, yeah.
- 23:28Jane Barratt (Host): Yeah, Marios, perhaps if you can pick up on that, I'm really intrigued about your work in school children.
- 23:35Jane Barratt (Host): I think this is an area that requires further attention.
- 23:40Jane Barratt (Host): Do you see this, as research over the next decade?
- 23:46Marios Koutsakos: I mean, yeah, for sure.
- 23:48Marios Koutsakos: And I think the research using samples from children is inherently more complex in many ways.
- 23:56Marios Koutsakos: I think for me, one thing that I guess we need to be thinking more about the next decade is how to integrate more the different disciplines that we all work in.
- 24:08Marios Koutsakos: There's a lot of opportunities, and there's also a greater need, I think, for more interdisciplinary science.
- 24:14Marios Koutsakos: That includes more basic science, more translational science, more veterinary science, more zoonotic assessments, and more of the computational, I guess, aspects that we see coming up quite quickly over the last few years.
- 24:27Marios Koutsakos: So I think for me, finding better ways to integrate the interdisciplinary aspects of our science will be quite important.
- 24:37Jane Barratt (Host): Look, thank you.
- 24:38Jane Barratt (Host): Now, if you're really talking to someone who's just starting their PhD or facing setbacks, what's the one piece of information, advice that you would impart?
- 24:54Jane Barratt (Host): So take yourself back to when you were just starting, and what's the one piece of advice that you would say, ah, that helped me keep moving forward?
- 25:05Jane Barratt (Host): So, Kevin, and then Marios?
- 25:08Kevin Ciminski: So when you start your PhD, you are highly motivated.
- 25:12Kevin Ciminski: That's good, and you need it.
- 25:14Kevin Ciminski: But you will very rapidly see that experiments fail.
- 25:19Kevin Ciminski: So you need to be very tolerant to frustration. And probably telling people that you do 90% of your experiments that are trash, they won't work, you will fail in 90%, but you do it for the 10% that work, and that will shed light on something no one ever has done before.
- 25:40Kevin Ciminski: So you need to go for the 10% that work out.
- 25:43Kevin Ciminski: So failure is good.
- 25:45Kevin Ciminski: It is necessary because you will see what doesn't work.
- 25:50Kevin Ciminski: It will teach you something, and then you have to rethink, recalibrate your research idea and your hypothesis, and then you go back and do another one.
- 26:01Jane Barratt (Host): I couldn't agree with you more.
- 26:02Jane Barratt (Host): So, Marios?
- 26:04Marios Koutsakos: No, I agree as well.
- 26:05Marios Koutsakos: I think you know, finding a way to develop that resilience against the inevitable failure is key.
- 26:15Marios Koutsakos: And I think what helps there is remembering why you want to do this in the first place and what drives you to get up in the morning and go and try that experiment again and hope for the best, or yeah, I think developing that sense of resilience is the key.
- 26:31Jane Barratt (Host): I think people in your field must have resilience because it's really that 10% that you're looking for.
- 26:39Jane Barratt (Host): Now, as we bring this podcast to a close, I'm going to ask both of you know what is the key message that you want, the audience to hear from you today?
- 26:50Jane Barratt (Host): So let's start with Kevin first.
- 26:53Jane Barratt (Host): Kevin, what's the one key thing that you want people to know from this podcast?
- 27:01Kevin Ciminski: Stay curious and stay open-minded.
- 27:04Kevin Ciminski: That's not only a take-home message for science, but I think for the entire life.
- 27:11Jane Barratt (Host): I'll take that one.
- 27:12Jane Barratt (Host): Thank you.
- 27:12Jane Barratt (Host): And Marios?
- 27:14Marios Koutsakos: I couldn't agree more.
- 27:15Marios Koutsakos: I think the open-mindedness and curiousness is fundamental to science and life.
- 27:21Marios Koutsakos: I guess the other thing that I would try to advise people is to believe in science and the work that people do.
- 27:33Marios Koutsakos: Don't believe everything else you hear out there, scientists do have the best interest in mind.
- 27:41Jane Barratt (Host): You know, you've both been an inspiration to me today.
- 27:44Jane Barratt (Host): It's a great honor to be able to be in conversation with you both.
- 27:50Jane Barratt (Host): As young scientists, you know, I am very hopeful for the future.
- 27:55Jane Barratt (Host): What you've talked about is not only the essence of your work, but the people who you are.
- 28:01Jane Barratt (Host): And there takes a certain, as we say, resilience and courage and tenacity to be who you are and to lead the teams that you do.
- 28:11Jane Barratt (Host): So I want to thank both of you for your insights and the work that you're doing in advancing our understanding of influenza and respiratory viruses.
- 28:21Jane Barratt (Host): And thank you to our listeners for joining us for this episode of ESWI Airborne.
- 28:27Jane Barratt (Host): To learn more about ESWI and our community of scientists, clinicians, and public health leaders, visit eswi.org.
- 28:36Jane Barratt (Host): We really do look forward to continuing, this early career scientist series with more voices shaping the future of our field.
- 28:46Jane Barratt (Host): But today, we've had the great pleasure of talking with Dr.
- 28:50Jane Barratt (Host): Kevin Ciminski and Dr.
- 28:53Jane Barratt (Host): Marios Koutsakos.
- 28:54Jane Barratt (Host): Thank you very much for your time today.
- 29:01ESWI Secretariat: ESWI Airborne is brought to you by ESWI, the European Scientific Working Group on Influenza and other acute respiratory viruses.
- 29:09ESWI Secretariat: These episodes would not be possible without the team's efforts, and we would like to extend special thanks to our ESWI Secretariat, our technical and IT teams, our arts team, and our host Jane Barrett.
- 29:22ESWI Secretariat: The podcasts are recorded virtually, and we thank our guests for their participation in this inspiring series.
- 29:29ESWI Secretariat: Talks are adapted to a global audience and are intended to be educational.
- 29:33ESWI Secretariat: For any specific medical questions you may have, these should be addressed to your local general practitioner.
- 29:40ESWI Secretariat: Many thanks to our sponsoring partners, and thank you for listening.